Literature DB >> 2439949

Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex.

M F Beal, M F Mazurek.   

Abstract

Substance P is an undecapeptide which has been found in human cortical neurons. We measured concentrations of this peptide in Alzheimer's disease (AD) and control postmortem tissue by radioimmunoassay. Using high-performance liquid chromatography, most of the immunoreactivity from AD or control temporal cortex comigrated with synthetic standards. Significant reductions of 20 to 40% in substance P-like immunoreactivity were found in AD cerebral cortex and hippocampus, most severe in the inferior temporal gyrus. Substance P neurons or their terminals are vulnerable to the pathophysiologic process in AD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439949     DOI: 10.1212/wnl.37.7.1205

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor.

Authors:  A Marighetto; K Touzani; N Etchamendy; C C Torrea; G De Nanteuil; D Guez; R Jaffard; P Morain
Journal:  Learn Mem       Date:  2000 May-Jun       Impact factor: 2.460

2.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.

Authors:  K Toide; T Fujiwara; Y Iwamoto; M Shinoda; K Okamiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

3.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

Review 4.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

5.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.

Authors:  N W Kowall; M F Beal; J Busciglio; L K Duffy; B A Yankner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

6.  Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.

Authors:  P Morain; J L Robin; G De Nanteuil; R Jochemsen; V Heidet; D Guez
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 7.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.

Authors:  Nick Pantaleo; Wayne Chadwick; Sung-Soo Park; Liyun Wang; Yu Zhou; Bronwen Martin; Stuart Maudsley
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

8.  Transcriptomics Profiling of Alzheimer's Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, and Deregulated Expression of Long Noncoding RNAs.

Authors:  Marco Magistri; Dmitry Velmeshev; Madina Makhmutova; Mohammad Ali Faghihi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.